Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment
Vensica Medical has secured an $11 million funding round led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie. The funding will support Phase 2 clinical trials in the US and Europe for their innovative overactive bladder (OAB) treatment. The company's proprietary technology delivers botulinum toxin A (Xeomin®) through a needle-free device directly to the bladder wall, offering a potentially less invasive alternative to traditional injections. Through its partnership with Merz, Vensica has obtained exclusive rights to Xeomin® for needle-less applications in various urologic indications.
Vensica Medical ha ottenuto un finanziamento di 11 milioni di dollari, guidato dal Israel Biotech Fund (IBF), con la partecipazione di partner strategici come Merz e Laborie. Il finanziamento supporterà la fase 2 degli studi clinici negli Stati Uniti e in Europa per il loro innovativo trattamento per l'iperattività della vescica (OAB). La tecnologia proprietaria dell'azienda somministra la tossina botulinica A (Xeomin®) attraverso un dispositivo senza ago direttamente alla parete della vescica, offrendo un'alternativa potenzialmente meno invasiva rispetto alle iniezioni tradizionali. Attraverso la partnership con Merz, Vensica ha ottenuto diritti esclusivi su Xeomin® per applicazioni senza ago in varie indicazioni urologiche.
Vensica Medical ha conseguido una ronda de financiamiento de 11 millones de dólares liderada por el Israel Biotech Fund (IBF), con la participación de socios estratégicos como Merz y Laborie. La financiación apoyará los ensayos clínicos de Fase 2 en EE. UU. y Europa para su innovador tratamiento de la vejiga hiperactiva (OAB). La tecnología patentada de la compañía entrega toxina botulínica A (Xeomin®) a través de un dispositivo sin aguja directamente en la pared de la vejiga, ofreciendo una alternativa potencialmente menos invasiva a las inyecciones tradicionales. A través de su asociación con Merz, Vensica ha obtenido derechos exclusivos sobre Xeomin® para aplicaciones sin aguja en diversas indicaciones urológicas.
벤시카 메디컬은 이스라엘 바이오텍 펀드(IBF)가 주도하는 1100만 달러의 자금 조달 라운드를 확보했으며, 전략 파트너로 Merz와 Laborie가 참여했습니다. 이 자금은 미국과 유럽에서의 혁신적인 과활동성 방광(ОAB) 치료법에 대한 2단계 임상 시험을 지원할 것입니다. 회사의 독점 기술은 보툴리눔 톡신 A (Xeomin®)를 바늘 없는 장치를 통해 방광 벽에 직접 전달하여 전통적인 주사보다 덜 침습적인 대안을 제공합니다. Merz와의 파트너십을 통해 Vensica는 다양한 비뇨기학적 적응증에 대한 바늘 없는 애플리케이션에 대해 Xeomin®에 대한 독점 권리를 확보했습니다.
Vensica Medical a sécurisé une levée de fonds de 11 millions de dollars dirigée par l'Israel Biotech Fund (IBF), avec la participation de partenaires stratégiques tels que Merz et Laborie. Ce financement soutiendra les essais cliniques de Phase 2 aux États-Unis et en Europe pour leur traitement innovant de la vessie hyperactive (OAB). La technologie propriétaire de l'entreprise délivre la toxine botulique A (Xeomin®) via un dispositif sans aiguille directement à la paroi de la vessie, offrant une alternative potentiellement moins invasive aux injections traditionnelles. Grâce à son partenariat avec Merz, Vensica a obtenu des droits exclusifs sur Xeomin® pour des applications sans aiguille dans diverses indications urologiques.
Vensica Medical hat eine Finanzierungsrunde von 11 Millionen Dollar gesichert, die vom Israel Biotech Fund (IBF) geleitet wurde, mit der Teilnahme von strategischen Partnern wie Merz und Laborie. Die Finanzierung wird die Phase-2-Studien in den USA und Europa für ihre innovative Behandlung der überaktiven Blase (OAB) unterstützen. Die proprietäre Technologie des Unternehmens liefert Botulinumtoxin A (Xeomin®) über ein nadelfreies Gerät direkt an die Blasenwand und bietet eine potenziell weniger invasive Alternative zu herkömmlichen Injektionen. Durch die Partnerschaft mit Merz hat Vensica exklusive Rechte an Xeomin® für nadelfreie Anwendungen in verschiedenen urologischen Indikationen erworben.
- Secured $11 million in new funding
- Strategic partnerships with established companies Merz and Laborie
- Exclusive rights to Xeomin® for needle-less urologic applications
- Advancing to Phase 2 clinical trials in US and Europe
- Product still in clinical trial phase, not yet commercialized
- Requires successful completion of Phase 2 trials before potential market entry
Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive Treatment
The investment round was led by Israel Biotech Fund (IBF), alongside key strategic partners, Merz, a global player in neurotoxins, and Laborie, a prominent urology medical device company. This funding will enable Vensica to continue its mission of providing a minimally invasive, simple, and effective solution for people with overactive bladder ("OAB").
Vensica's unique technology leverages a needle-free drug delivery system, that administers Xeomin® directly to the bladder wall. This approach is expected to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica's needle-free drug delivery system aims to be a urology treatment platform for the treatment of additional bladder indications.
"We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment," remarked Avner Geva, CEO of Vensica. "This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it."
As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic application in several urologic indications and will benefit from Merz's clinical development support. This collaboration marks a significant step forward in the company's goal of delivering next-generation urology treatments.
For more information on Vensica and its upcoming clinical trials, visit https://vensica.com/.
About Vensica Medical
Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. The company's leading product is a needle-free delivery system for Xeomin® (botulinum toxin A) aimed at treating overactive bladder in a minimally invasive manner. Vensica was established in the incubator program of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority.
Contact:
Avner Geva, Chief Executive Officer
avner@vensica.com
Photo: https://mma.prnewswire.com/media/2541677/CTO_Co_Founder_Vensica_Medical.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder-treatment-302288449.html
SOURCE Vensica Medical
FAQ
What is the size of Vensica Medical's latest funding round?
What is Vensica Medical's new treatment method for overactive bladder?
What phase of clinical trials is Vensica Medical entering for their OAB treatment?
What exclusive rights has Vensica Medical secured from Merz?
